Jasvinder A Singh1,2,3, Shaohua Yu2. 1. Medicine Service, Birmingham VA Medical Center, Birmingham, Alabama, USA. 2. Division of Epidemiology, Department of Medicine School of Medicine, School of Public Health, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA. 3. Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Abstract
OBJECTIVE: To assess the effect of allopurinol dose/duration on the risk of renal failure in the elderly with allopurinol use. METHODS: We used the 5% random Medicare claims data from 2006 to 2012. Multivariable-adjusted Cox regression analyses assessed the association of allopurinol dose/duration with subsequent risk of developing incident renal failure or end-stage renal disease (ESRD) (no prior diagnosis in last 183 days) in allopurinol users, controlling for age, sex, race and Charlson-Romano comorbidity index. HRs with 95% CIs were calculated. Sensitivity analyses considered a longer baseline period (365 days), controlled for gout or used more specific codes. RESULTS: Among the 30 022 allopurinol treatment episodes, 8314 incident renal failure episodes occurred. Compared with 1-199 mg/day, allopurinol dose of 200-299 mg/day (HR 0.81; 95% CI 0.75 to 0.87) and ≥300 mg/day, 0.71 (0.67 to 0.76), had significantly lower hazard of renal failure in multivariable-adjustment model, confirmed in multiple sensitivity analyses. Longer allopurinol use duration was significantly associated with lower hazards in sensitivity analyses (365-day look-back; reference, <0.5 year): 0.5-1 year, 1.00 (0.88, 1.15); >1-2 years, 0.85 (0.73 to 0.99); and >2 years, 0.81 (0.67 to 0.98). Allopurinol ≥300 mg/day was also associated with significantly lower risk of acute renal failure and ESRD with HR of 0.89 (0.83 to 0.94) and 0.57 (0.46 to 0.71), respectively. CONCLUSIONS: Higher allopurinol dose is independently protective against incident renal failure in the elderly allopurinol users. A longer duration of allopurinol use may be associated with lower risk of incident renal failure. Potential mechanisms of these effects need to be examined. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To assess the effect of allopurinol dose/duration on the risk of renal failure in the elderly with allopurinol use. METHODS: We used the 5% random Medicare claims data from 2006 to 2012. Multivariable-adjusted Cox regression analyses assessed the association of allopurinol dose/duration with subsequent risk of developing incident renal failure or end-stage renal disease (ESRD) (no prior diagnosis in last 183 days) in allopurinol users, controlling for age, sex, race and Charlson-Romano comorbidity index. HRs with 95% CIs were calculated. Sensitivity analyses considered a longer baseline period (365 days), controlled for gout or used more specific codes. RESULTS: Among the 30 022 allopurinol treatment episodes, 8314 incident renal failure episodes occurred. Compared with 1-199 mg/day, allopurinol dose of 200-299 mg/day (HR 0.81; 95% CI 0.75 to 0.87) and ≥300 mg/day, 0.71 (0.67 to 0.76), had significantly lower hazard of renal failure in multivariable-adjustment model, confirmed in multiple sensitivity analyses. Longer allopurinol use duration was significantly associated with lower hazards in sensitivity analyses (365-day look-back; reference, <0.5 year): 0.5-1 year, 1.00 (0.88, 1.15); >1-2 years, 0.85 (0.73 to 0.99); and >2 years, 0.81 (0.67 to 0.98). Allopurinol ≥300 mg/day was also associated with significantly lower risk of acute renal failure and ESRD with HR of 0.89 (0.83 to 0.94) and 0.57 (0.46 to 0.71), respectively. CONCLUSIONS: Higher allopurinol dose is independently protective against incident renal failure in the elderly allopurinol users. A longer duration of allopurinol use may be associated with lower risk of incident renal failure. Potential mechanisms of these effects need to be examined. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Marie Pavlusova; Jiri Jarkovsky; Klara Benesova; Jiri Vitovec; Ales Linhart; Petr Widimsky; Lenka Spinarova; Kamil Zeman; Jan Belohlavek; Filip Malek; Marian Felsoci; Jiri Kettner; Petr Ostadal; Cestmir Cihalik; Jiri Spac; Hikmet Al-Hiti; Marian Fedorco; Richard Fojt; Andreas Kruger; Josef Malek; Tereza Mikusova; Zdenek Monhart; Stanislava Bohacova; Lidka Pohludkova; Filip Rohac; Jan Vaclavik; Dagmar Vondrakova; Klaudia Vyskocilova; Miroslav Bambuch; Gabriela Dostalova; Stepan Havranek; Ivana Svobodová; Ladislav Dusek; Jindrich Spinar; Roman Miklik; Jiri Parenica Journal: Clin Cardiol Date: 2019-05-29 Impact factor: 2.882
Authors: Karel H van der Pol; Kimberley E Wever; Mariette Verbakel; Frank L J Visseren; Jan H Cornel; Gerard A Rongen Journal: PLoS One Date: 2021-12-02 Impact factor: 3.240
Authors: Rishi J Desai; Jessica M Franklin; Julia Spoendlin-Allen; Daniel H Solomon; Goodarz Danaei; Seoyoung C Kim Journal: PLoS One Date: 2018-02-28 Impact factor: 3.240
Authors: Matthew Roughley; Alyshah Abdul Sultan; Lorna Clarson; Sara Muller; Rebecca Whittle; John Belcher; Christian D Mallen; Edward Roddy Journal: Arthritis Res Ther Date: 2018-10-30 Impact factor: 5.156